Introduction
============

Photothermal therapy (PTT), a promising and targeted approach against cancer, has attracted considerable research attention.[@B1]-[@B7] PTT employs photothermal agents to efficiently harvest laser energy and convert it into heat to selectively destruct cancer cells.[@B8]-[@B11] In order to monitor the treatment process, reduce the toxic side effects to normal cells and tissues, and maximize treatment efficacy, in situ visualization of the therapeutic process is of high importance for precision therapy.[@B12] To date, several imaging methods, including thermal imaging with infrared camera, and magnetic resonance imaging, have been widely applied for the visualization of temperature changes during the therapeutic process [@B13]-[@B16]. These techniques undoubtedly provide more important information for the further optimization of therapeutic protocols and improvement of treatment efficacy. However, the available technologies are highly dependent on the macroscopic temperature distribution of lesion tissue. In cancer PTT with functional nanoagents, photothermal heating is first generated at the microscale, with a slow subsequent spread of the heat. The temperature-feedback processes at the macro scale thus greatly increase the risk of damage to normal cells and tissues through heat conduction [@B12]. Therefore, the development of a visualization strategy remains a major challenge in situ for the sensitive monitoring of the treatment process and precise reporting of the therapeutic response, below macro scale or even micro scale.

Förster resonance energy transfer (FRET) is an energy exchange process from a donor fluorophore to an acceptor chromophore via non-radiative dipole-dipole coupling [@B17]. The FRET efficiency strongly depends on the distance and spectral overlap between the donor and nearby acceptor molecules [@B18]. Comparing with conventional fluorescence imaging techniques, FRET-based imaging has several inherent advantages, including (1) reduced crosstalk between excitation and emission light by large Stokes shifts [@B19], (2) high accuracy from an intrinsic reference of donor or acceptor fluorophores,[@B20] and (3) high contrast sensitivity due to an improved signal to background (S/B) ratio.[@B21] Due to these advantages, FRET-based fluorescence imaging has been applied as nanothermometers for temperature sensing in live cells [@B22], [@B23]. Recently, Ng *et al.* [@B24] reported bacteriopheophorbide-lipid (energy acceptor) doped porphysomes (energy donor) for in situ monitoring of the structural integrity of the porphysomes themselves. It is claimed that the FRET-based porphysomes are potentially able to guide optimal treatment time of PTT. However, *in vivo* application of FRET-based fluorescence imaging with high spatial resolution for in situ visualization of cancer PTT remains a challenge [@B25].

Photoacoustic (PA) imaging employs a pulsed light to excite the imaged object and an ultrasonic transducer to detect the acoustic signal.[@B26]-[@B31] It has high optical contrast and low ultrasonic scattering, leading to multiscale imaging capabilities of high resolution and deep penetration.[@B32]-[@B35] As an alternative and innovative approach, PA imaging of FRET was first reported by Wang *et al.*,[@B36]-[@B38] who achieved a better performance than fluorescence imaging of FRET, with sub-micron spatial resolution and centimeter scale of penetration depth. During the PA imaging of FRET, the PA signal of FRET pairs increases with decreasing donor fluorescence emission.[@B37] This opposite process offers a novel opportunity to visualize photothermal ablation using FRET-based NIR fluorescence and PA dual-modal imaging technique. Therefore, it is essential to develop theranostic nanoprobes (NPs) with an efficient energy transfer pair to assess photothermal responses and in situ visualization of cancer PTT, thus improving the therapeutic efficacy.

Herein, we demonstrate a theranostic NP with FRET-based NIR fluorescence and PA dual-modal imaging functions for the observation of cancer PTT in situ. The NP is synthesized via molecular self-assembly and chemical crosslinking method (Figure [1](#F1){ref-type="fig"}a). Methylene blue (MB) and indocyanine green (ICG), as donor-acceptor pairs, are inserted into the various domains of human serum albumin (HSA) matrix and further cross-linked by glutaraldehyde, leading to the formation of HSA-ICG-MB NPs. The obtained NPs possess several remarkable advantages. First, they have a robust biosafety; ICG and MB are FDA-approved dyes, and HSA is a drug delivery vehicle commonly used in the clinic [@B39]-[@B45]. Second, they provide precision theranostics; HSA-ICG-MB NPs possess dual-modal contrast, efficient photothermal ablation, and FRET-based self-sensing features. Therefore, they can precisely indicate the exact location and timing of HSA-ICG-MB NP delivery, as well as their treatment efficacy and response [@B46]-[@B48]. With the above priorities, the highly well-designed NPs are expected to be subsequently applied for cancer theranostics.

Materials and Methods
=====================

Materials
---------

HSA, PI, dimethyl sulfoxide, MB, Calcein AM, ICG, 4,6-diamidino-2-phenylindole (DAPI) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), were purchased from Sigma Aldrich. PBS (pH 7.4), RPMI 1640 medium, fetal bovine serum, trypsin-EDTA, and penicillin-streptomycin were purchased from Gibco Life Technologies (AG, Switzerland). Ethanol and ethyl acetate were obtained from Sinopharm Chemical Reagent Co., Ltd. An NIR laser source (808 nm) was from Beijing Laserwave Optoelectronics Tech. Co., Ltd.

Characterization
----------------

The absorption and fluorescence emission spectra were performed by PerkinElmer Lambda 750 absorption spectrophotometer and fluorescence spectrophotometer (F900, Edinburgh Instruments, Ltd.), respectively. TEM imaging was carried out in a FEI Tecnai G2 F20 S-Twin (FEI, 200 kV, USA). The hydrodynamic diameter of the NPs was determined by a Malvern Zetasizer Nano ZS. *In vitro* PA measurements were conducted with AR-PAM system [@B34].

Preparation of HSA-ICG-MB NPs
-----------------------------

In a typical synthesis, 80 mg HSA and 3.2 mg MB were firstly dissolved in 2 mL of water. Then, the solution was quickly mixed with 8 mL of ethanol (containing 12.8 mg ICG) under continuous stirring (600 rpm) at room temperature. The obtained HSA-ICG-MB complex was further crosslinked by glutaraldehyde (2%). Finally, the suspension was centrifuged at 20,000 rpm for 30 min at 4 ^o^C to removing the organic solvents, unencapsulated dyes, and excess HSA. The pellet was then resuspended in PBS for further experiments.

Determination of FRET efficacy
------------------------------

The fluorescence spectra of HSA-ICG-MB complex with different ICG/MB ratios were measured with excitation wavelength at 600 nm. C~HSA~ = 125 µg/mL, C~MB~ = 5 µg/mL, C~ICG~ = 0, 2.5, 5, 10, 15 µg/mL. The FRET efficacy between ICG and MB in NPs is determined by comparing the changes of MB fluorescence before and after adding ICG acceptor. The quantitative equation is as follows: E = (1-I~b~/I~a~)×100%, where I~a~ is the fluorescence intensity of the MB donor in the absence of ICG acceptor, and I~b~ is the fluorescence in the presence of ICG acceptor.

*In vitro* release behavior
---------------------------

The release process of ICG and MB from HSA-ICG-MB NPs was investigated using a dialysis method. The prepared NP solution (0.5 mg/mL, 10 mL) was transferred into a dialysis tube (molecular weight cutoff 3500). Then, it was immersed in 50 mL of releasing solution (phosphate buffered saline, pH 7.4), and gently shaken at 37 ^o^C at 100 rpm. At different time intervals, 1 mL of release solution was withdrawn for UV-Vis analysis, and an equal volume of fresh media was added.

*In Vitro* Cytotoxicity
-----------------------

The mouse brain endothelial cell line bEnd.3 and the C6 rat glioma cell line were cultured in RMPI 1640 cell media. Cells were first seeded into 96-well plates at a density of 1.0 × 10^4^ cells per well. These cells were then incubated with HSA-ICG-MB NPs at various concentrations (0.3, 0.6, 1.2, 2.5, 5, 10 µg/mL) in a humidified incubator at 37 ^o^C with 5% CO~2~ for 24 h and 48 h respectively. The standard MTT cell viability assay was used to determine the relative cell cytotoxicity of HSA-ICG-MB NPs.

Cellular Uptake of HSA-ICG-MB NPs
---------------------------------

For *in vitro* studies, C6 glioma and bEnd.3 cells (1 × 10^5^ cells) were seeded on eight-well glass-bottomed culture dishes. After 24 h, the cells were incubated for 3 h with HSA-ICG-MB NPs or free ICG at 37 ^o^C before confocal analysis, C~ICG~ = 2.5 μg/mL. A laser scanning confocal microscope (Leica TCS SP5) was used to image the cells. Cell nuclei were stained blue with DAPI.

*In Vitro* Visualization of PTT
-------------------------------

For visualization of cellular PTT, C6 glioma cells (1.0 × 10^5^ cells) were seeded on eight-well glass-bottomed culture dishes. After 24 h, the cells were incubated for 3 h with HSA-ICG-MB NPs at 37^o^C, C~ICG~ = 2.5 μg/mL. After being rinsed with PBS, the cells were exposed to NIR laser (808 nm, 1.0 W/cm^2^) for 0, 2 and 5 min. The macroscopic temperature variation of the wells was detected by thermal imaging. The photothermal responses were assessed by a laser confocal microscope with an excitation wavelength at 633 nm and emission wavelength at 640-690 nm (MB channel) and 690-760 nm (ICG channel).

To evaluate photothermal responses with PA imaging, the C6 glioma cells (100,000) were collected and embedded in agarose after photothermal treatments (808 nm, 1.0 W/cm^2^, 0-5 min). PA imaging was obtained with a photoacoustic computerized tomography scanner (Endra Nexus 128, Ann Arbor, MI).

In Vitro PTT
------------

C6 glioma cells were seeded in 96-well plates and mixed with various concentrations (0, 0.07, 0.15, 0.3, 0.6, 1.2, 2.5 µg/mL) of HSA-ICG-MB NPs. After 3 h, the plates were rinsed with PBS and immersed in fresh culture medium. Then, the cells were exposed to light at 808 nm wavelength at a power density of 1.0 W/cm^2^ for 5 min. The standard MTT cell viability assay was used to determine relative cell viabilities.

The cell survival ratio was also studied by Calcein AM and PI co-staining. C6 glioma cells seeded in 96-well plates were mixed with HSA-ICG-MB NPs (C~ICG~ = 2.5 μg/mL). After 3 h, the plates were rinsed with PBS and immersed in fresh culture medium. Then, the cells were exposed to the 808 nm light at a power density of 1.0 W/cm^2^ for 5 min. After another 4 h, the cells were stained with Calcein AM and PI. The cells were then rinsed again with PBS and examined with an inverted microscope (Olympus IX71, JPN).

Animal model
------------

BALB/c athymic nude mice (5-8 weeks old) were obtained from the Beijing Laboratory Animal Research Center. All animal experiment procedures were approved by and performed under the guidelines of the Animal Study Committee of Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. 5 × 10^6^ C6 glioma cells were suspended and injected into the back of Balb/c nude mice. Tumor-bearing mice were used for subsequent imaging experiments and PTT when the tumor size reached \~60 mm^3^.

*In Vivo* Imaging and Biodistribution Studies
---------------------------------------------

The FRET-based NIR fluorescence imaging studies were performed as the tumor size reached \~60 mm^3^. HSA-ICG-MB NPs (0.5 mg ICG/kg) were intravenously injected into mice (n = 3), and the fluorescence images were acquired on an IVIS fluorescence imaging system. MB channel with the excitation of 640 nm and emission of 700 nm, ICG channel with the excitation of 710 nm and emission of 800nm, and FRET channel with the excitation of 640 nm and emission of 800 nm. At 24 h post injection of NPs, all mice were euthanized, and tumors, as well as all major organs, were collected for *ex vivo* imaging. PA imaging *in vivo* was obtained with a photoacoustic computerized tomography scanner (Endra Nexus 128). ICG PA imaging channel was used with the excitation of 780 nm, and MB imaging channel was obtained with the excitation of 680 nm.

Blood Circulation
-----------------

To detect the pharmacokinetics of HSA-ICG-MB NPs, the BALB/c mice were randomly divided into 8 groups (n = 5 per group). After injection of NPs, 100 μL of blood samples were drawn from mice NPs at different time points (0, 1, 2, 3, 4, 5, 10, and 24 h), and mixed with 900 μL of lysis buffer. ICG concentration was detected by fluorescence spectroscopy.

*In Vivo* Visualization of PTT
------------------------------

For *in situ* visualization of cancer PTT, 9 nude mice bearing C6 tumors at 24 h post injection of NPs (2 mg ICG/kg) were randomly divided into three groups. The imaging scheme is as follows: (1) Thermal imaging with an infrared thermal imaging camera (Ti27, Fluke, USA); (2) FRET-based fluorescence imaging with MB, ICG and FRET channels (IVIS fluorescence imaging system) and (3) PA imaging of FRET with excitation wavelength of 680 nm and 780 nm (Endra Nexus 128), respectively.

*In Vivo* PTT
-------------

For *in vivo* PTT, 20 mice bearing C6 glioma tumors (tumor size of ∼60 mm^3^) were randomly divided into four treatment groups: (1) PBS; (2) laser; (3) HSA-ICG-MB NPs (2 mg ICG/kg); and (4) HSA-ICG-MB NPs-laser (2 mg ICG/kg). The tumor sizes and body weights were recorded every 3 days. The tumor volume was calculated using the formula: length×(width)^2^/2. Following therapy, tumors, as well as all major organs, were collected and sectioned to 8 μm slices for H&E staining and TUNEL assay.

Toxicology Evaluation
---------------------

2 and 4 mg/kg of NPs were injected into mice (n = 5). Physiological saline treated group was used as control. At 30 days post injection of NPs, the blood from treated mice was collected for blood biochemistry analysis. The major organs of the two treated groups were harvested, and the tissue slices were stained with H&E, and observed on the digital microscope.

Results and Discussion
======================

Design and Characterization of the NPs
--------------------------------------

Due to the high affinity of ICG/MB to HSA, the two dyes were simultaneously inserted into the subdomain of HSA matrix via highly hydrophobic interactions.[@B49],[@B50] Molecular docking was performed using AutoDock Vina software in order to visually reveal the binding modes of ICG/MB within HSA. The simulation results indicate that ICG and MB could selectively bind to the subdomain IIA of HSA, and the distance of the two dyes is less than 2 nm (Figure [1](#F1){ref-type="fig"}b). Additionally, the fluorescence emission spectrum of MB remarkably overlaps with the absorbance spectrum of ICG (Figure [1](#F1){ref-type="fig"}c). These features would pave the way for the development of an efficient FRET system inside the HSA matrix, where MB and ICG serve as a donor-acceptor pair. As shown in Figure [1](#F1){ref-type="fig"}d, when the molar ratio of ICG/MB was increased, the fluorescence intensity of the MB donor was considerably quenched, and the fluorescence intensity of the ICG acceptor at 810 nm increased gradually. The FRET efficiency improved dramatically from 0 to 86.8% with an increase in ICG/MB ratio from 0 to 3 (Figure [S1](#SM0){ref-type="supplementary-material"}). To explore the PA detection of FRET, a 600 nm laser pulse was employed to excite the MB donor, and a megahertz ultrasound transducer was used to detect acoustic signals. The PA signals of the MB donor enhanced significantly with increasing ICG/MB ratio (Figure [1](#F1){ref-type="fig"}e), while PA signal variations of ICG were not so obvious (Figure [S2](#SM0){ref-type="supplementary-material"}), indicating that the fluorescence quenching of MB triggers PA signal enhancement of the FRET pair. Subsequently, the HSA-ICG-MB complex with different ICG/MB ratios was further cross-linked by glutaraldehyde, resulting in the formation of HSA-ICG-MB NPs (Table [S1](#SM0){ref-type="supplementary-material"}). The maximum FRET efficacy of ICG and MB in NPs was measured to be 88.2%, which is similar to that in HSA matrix. The binding ratios of ICG and MB to HSA were measured to be 7:1 and 5:1, respectively. [@B51]

Transmission electron microscopy (TEM) demonstrates that the main diameter of the optimized HSA-ICG-MB NPs is 75.0 nm, illustrating their well-defined spherical morphology and homogeneous size distribution (Figure [1](#F1){ref-type="fig"}f). The hydrodynamic diameter of the obtained NPs is \~110.0 nm, as measured by dynamic light scattering (Figure [1](#F1){ref-type="fig"}g). HSA-ICG-MB NPs demonstrate excellent colloidal stability at 4°C in the dark, and there were no obvious size variations following storage over 10 weeks (Figure [1](#F1){ref-type="fig"}h), indicating a high colloidal stability. Moreover, the size of the NPs remained unchanged at 37°C for 24 h in PBS, indicating their excellent durability in physiological conditions (Figure [S3](#SM0){ref-type="supplementary-material"}). The release profiles *in vitro* of ICG and MB in NPs show a delayed release in phosphate buffered saline (PBS) (Figure [S4](#SM0){ref-type="supplementary-material"}), serum (Figure [S5](#SM0){ref-type="supplementary-material"}) and medium solution (Figure [S6](#SM0){ref-type="supplementary-material"}), demonstrating the strong binding force between ICG/MB and HSA.

Monitoring of the Photothermal Effect of NPs
--------------------------------------------

The photothermal effect of HSA-ICG-MB NPs was monitored with FRET-based fluorescence and PA techniques (Figure [2](#F2){ref-type="fig"}a). Upon NIR laser irradiation (808 nm, 1.0 W/cm^2^, 5 min), the temperature of the HSA-ICG-MB NPs quickly increased from 26.5^o^C to 59.2^o^C, while there was a slight rise from 26.5^o^C to 28.6^o^C in the PBS group (Figure [2](#F2){ref-type="fig"}b). This demonstrates that HSA-ICG-MB NPs are efficient photothermal transducers to produce significant hyperthermia (\>42^o^C).[@B52] During photothermal heating, the ICG molecules in NPs gradually decompose [@B53], [@B54], and their FRET efficiency accordingly decreases, resulting in changes in the fluorescence and PA signals of the donor-acceptor pair. It was observed that with increasing temperature, the fluorescence intensity of ICG (centered at 810 nm) decreased, while MB emission (centered at 685 nm) enhanced correspondingly (Figure [2](#F2){ref-type="fig"}c). Moreover, the fluorescence intensity ratio of MB to ICG showed a linear relationship with the photothermal temperature from 26.5 ^o^C to 59.2 ^o^C (Figure [2](#F2){ref-type="fig"}d). The linear equation can be expressed as y = -51.43x + 60.736 (R² = 0.9985), x is the fluorescence intensity ratio (I~810~/I~685~) and the detection limit was 0.5 ^o^C (S/N = 3), thus indicating a high sensitivity.[@B55] Furthermore, the PA signal of the FRET pair simultaneously declined with increasing photothermal temperature (Figure [2](#F2){ref-type="fig"}e). The temperature plotted against ln(I~780~/I~600~) indicates a linear relationship in the detection range from 26.5^o^C to 59.2^o^C, with a sensitivity of 0.7 ^o^C (S/N = 3) (Figure [2](#F2){ref-type="fig"}f). These results demonstrate that the prepared HSA-ICG-MB NPs can efficiently produce hyperthermia with simultaneous sensitive monitoring of the photothermal effect, which lays an important foundation for visualization of cancer PTT.

FRET-based *In Vitro* Visualization of PTT
------------------------------------------

The cell internalization of HSA-ICG-MB NPs in C6 glioma cells and bEnd.3 endothelial cells was assessed through confocal fluorescence microscopy (Figure [3](#F3){ref-type="fig"}a). The NPs exhibit low cytotoxicity for bEnd.3 cells and C6 cells (Figure [S7](#SM0){ref-type="supplementary-material"}). After 3 h incubation, a considerable amount of NPs entered the cytoplasm of C6 glioma cells, exhibiting strong red fluorescence with an excitation wavelength at 633 nm and emission wavelength at 690-760 nm (ICG channel). In contrast, a minimal amount of free ICG was observed in C6 glioma cells. This indicates that HSA, as a delivery vehicle, enhances the cellular uptake of NPs.[@B56],[@B57] When the NPs were incubated with bEnd.3 endothelial cells, only a low fluorescence signal was observed, demonstrating the outstanding tumor-targeting ability of NPs.[@B53] A possible reason is the presence of overexpressed albumin-binding proteins, such as SPARC (secreted protein, acidic and rich in cysteine) and gp60, in glioma cells. The HSA-ICG-MB NPs binding with these receptors enhanced the cell uptake efficacy of the NPs. [@B58]

Under 808 nm laser irradiation (1.0 W/cm^2^, 0-5 min), the temperature of C6 glioma cells incubated with NPs increased from 37.0 ^o^C to 55.2 ^o^C (Figure [S8](#SM0){ref-type="supplementary-material"}), while laser-treated groups generated almost negligible temperature variation, indicating that the endocytic NPs can efficiently convert light energy to local hyperthermia (\> 42.0 ^o^C) for ablation of cancer cells. During the process, the fluorescence signal from MB gradually rose, and the fluorescence emission from ICG decreased monotonically with prolonged irradiation time from 0 to 5 min (Figure [3](#F3){ref-type="fig"}b). These changes stem from photothermal decomposition of ICG in NPs,[@B54] decreasing the FRET efficiency. Therefore, FRET-based dual-channel fluorescence imaging can be applied for clear visualization of the cellular therapeutic responses. In addition, to evaluate the PA imaging of FRET in cells, C6 glioma cells (100,000) were collected and embedded in agarose after photothermal treatment (808 nm, 1.0 W/cm^2^, 0-5 min). PA images of biological phantoms containing C6 glioma cells show that the signals from MB and ICG channels declined with increasing irradiation time (Figure [3](#F3){ref-type="fig"}c), revealing the potential of PA imaging of FRET at cellular levels. Therefore, the HSA-ICG-MB NPs with good tumor-targeting ability can be applied in the dual-modal visualization of cellular PTT.

In order to qualitatively assess the treatment efficiency, calcein-AM with green fluorescence and propidium iodide (PI) with red fluorescence were used to evaluate live and dead/late apoptotic cells, respectively. The control and laser-treated groups showed a green fluorescence (Figure [3](#F3){ref-type="fig"}d), indicating that either pure laser irradiation or only NPs is not able to destroy cancer cells. The NP-laser treated group demonstrated a time-dependent treatment process. After 5 min irradiation (808 nm, 1.0 W/cm^2^), most of the C6 glioma cells were killed, exhibiting an intense red fluorescence. The quantitative results further demonstrate that the NP-mediated PTT efficacy is dependent on NP concentration and irradiation time (Figure [3](#F3){ref-type="fig"}e). The optimal PTT (2.5 µg/mL, 5 min) was able to induce cell death up to 94.8%, showing high therapeutic efficacy.

*In Vivo* Dual-Modal Imaging
----------------------------

The feasibility of HSA-ICG-MB NPs for fluorescence and PA dual-modal imaging was investigated in C6 tumor-bearing mice with a tumor volume of \~60 mm^3^. Under an excitation wavelength of 640 nm and an emission wavelength of 700 nm (MB channel), the tumor site could not be clearly visualized at 24 h post injection due to the high background fluorescence of mice (S/B = 3.7) (Figure [4](#F4){ref-type="fig"}a). With a red-shift of the emission wavelength from 700 nm to 810 nm, the background fluorescence signal obviously decreased, and the fluorescence intensity in tumor tissue increased gradually over time, reaching a peak at 24 h post injection of the NPs (ICG channel, S/B = 7.6). These results suggest that fluorescence imaging *in vivo* with a longer emission window is able to significantly reduce the background signal and improve the S/B ratio. At an excitation wavelength of 640 nm and emission wavelength of 800 nm, the fluorescence imaging of FRET is obtained (FRET channel). The tumor could be clearly observed, showing a higher S/B ratio (14.5) than that of MB channel (3.7) and ICG channel (7.6) at 24 h post injection (Figure [4](#F4){ref-type="fig"}a,c). Therefore, the fluorescence imaging of FRET *in vivo* with a large Stokes shift and longer emission wavelength inhibits the crosstalk between the excitation and the emission light, decreases the background fluorescence, and improves the S/B ratio, revealing the great potential to clearly visualize cancer PTT. The *ex vivo* images of major organs and tumor tissue show a large accumulation of NPs in the liver and tumor (Figure [4](#F4){ref-type="fig"}d and Figure [S9](#SM0){ref-type="supplementary-material"}), and a small accumulation of ICG molecules released from HSA-ICG-MB NPs in the kidneys, suggesting a general metabolic pathway and high tumor accumulation of NPs. The pharmacokinetic analysis indicates that the blood circulation half-life of NPs is 3.4±0.4 h (Figure [S10](#SM0){ref-type="supplementary-material"}), revealing the long blood circulation time of HSA-ICG-MB NPs.

Comparing with fluorescence imaging, PA imaging, as a hybrid modality, could provide a deep imaging depth with high resolution, which is highly useful in the visualization of intratumoral accumulation and distribution of NPs.[@B59] To avoid the effect of endogenous hemoglobin with high PA contrast (680 nm excitation), *in vivo* PA imaging of tumor-bearing nude mice was performed with 780 nm plus laser as an excitation wavelength. As shown in Figure [4](#F4){ref-type="fig"}b, a low PA background signal from endogenous hemoglobin in blood vessels was observed prior to intravenous injection of NPs. At 3 h post injection of NPs, tumor blood vessels become brighter due to the presence of the NPs. With the prolongation of injection time, the PA signal in tumor blood vessels further increased, meanwhile, the surrounding tumor tissue was also clearly observed. This demonstrates that the NPs can easily enter the tumor by diffusion through the disrupted tumor blood vessels due to the enhanced permeability and retention effect and active targeting ability.[@B58],[@B60],[@B61] Quantitative analysis shows that the PA signal in the tumor area increased steadily over time, reaching a maximum value at 24 h post injection (Figure [4](#F4){ref-type="fig"}e). Thus, FRET-based fluorescence imaging with high S/B ratio provides a clear process of NP accumulation in tumor, while PA imaging with long excitation wavelength indicates the morphology of intratumoral blood vessels and the dynamic process of NPs entering the tumor, revealing great potential for guiding cancer PTT.

FRET-based *In Vivo* Visualization of Cancer PTT
------------------------------------------------

The feasibility of FRET-based imaging for *in situ* visualization of cancer PTT with HSA-ICG-MB NPs was investigated in subcutaneous C6 tumor-bearing mice (Figure [5](#F5){ref-type="fig"}a, b). Under the guidance of fluorescence and PA dual-modal imaging, the NIR laser (808 nm, 0.8 W/cm^2^) was precisely focused on the tumor region, and the macroscopic temperature variation in mice was detected by thermal imaging at 24 h post injection of NPs (Figure [S11](#SM0){ref-type="supplementary-material"}). The tumor treated with laser irradiation showed a moderate increase to 40.2 ^o^C, while the temperature of tumors in the NP-laser-treated group increased rapidly to 56.2 ^o^C (Figure [5](#F5){ref-type="fig"}c), indirectly revealing a high tumor accumulation and an efficient photothermal conversion of the NPs. To assess the photothermal effect at the microscale, FRET-based *in vivo* fluorescence and PA dual-modal imaging were performed. As shown in Figure [5](#F5){ref-type="fig"}a, with increasing photothermal temperature, the fluorescence signal from the MB channel steadily increased in the tumor region. In contrast, the fluorescence intensity of the ICG channel gradually decreased, revealing FRET-based efficient self-feedback capability of HSA-ICG-MB NPs. Moreover, when the FRET-based detection window was applied, the fluorescence signal from the laser irradiated tumor site gradually decreased and almost disappeared after 5 min (Figure [5](#F5){ref-type="fig"}a). The S/B ratios in the FRET channel were much higher than that of the ICG and MB channels at different time intervals (Figure [5](#F5){ref-type="fig"}d), indicating a high sensitivity of FRET fluorescence imaging for in situ visualization of cancer PTT.

Meanwhile, PA imaging *in vivo* was employed to monitor the treatment process. 680 nm (MB channel) and 780 nm (ICG channel) pulsed lasers were applied to excite the FRET pair of MB and ICG, respectively (Figure [5](#F5){ref-type="fig"}b). In the ICG channel, the dendritic intratumoral vessels became indistinct after a photothermal treatment duration of 5 min, further demonstrating that ICG dye in NPs gradually degrades in the tumor region. Thus, the PA signal in the MB channel at the tumor site also decreased, which is in good agreement with the results *in vitro*. Quantitative results show that the average PA intensity of ICG and MB channels reduced by 78.2% and 57.5% (Figure [5](#F5){ref-type="fig"}e). This demonstrates that the application of FRET-based self-feedback HSA-ICG-MB NPs for PA imaging of PTT is feasible in tumor-bearing nude mice, which provides a novel imaging modality for in situ visualization of intratumoral changes during photothermal treatment. In future studies, a highly integrated system with imaging, therapy and monitoring features will be designed and set-up for the quantitative the feed-back of temperature *in vivo*.

Under the guidance of FRET-based dual-modal imaging, optimized therapeutic protocols with HSA-ICG-MB NPs were conducted for cancer PTT. The tumor region in C6 tumor-bearing nude mice were treated with NIR laser irradiation for 5 min (808 nm, 0.8 W/cm^2^). The antitumor efficiency was verified by analysis of tumor growth and survival rates of mice (Figure [6](#F6){ref-type="fig"}a,b). The PBS-, laser-, and NP-treated groups exhibited rapid tumor growth, suggesting that C6 brain tumor growth is not influenced by single NP treatment and pure laser irradiation (Figure [6](#F6){ref-type="fig"}d, Figure [S12](#SM0){ref-type="supplementary-material"}). The survival rate was nearly 0% on day 25 post treatment for all three groups. The NPs-laser-treated group exhibited a significant tumor growth suppression, with a 100% survival rate on day 50 and no tumor recurrence. According to hematoxylin and eosin (H&E) staining and TUNEL assay, there was no obvious tumor necrosis observed in PBS-, NP-, and laser-treated groups. In contrast, abundant karyolysis and sporadic necrosis was observed in the NPs-laser-treated group, indicating the typical features of thermal damage (Figure [6](#F6){ref-type="fig"}e, f). During the treatments, there was almost no obvious change in body weight for C6 tumor-bearing nude mice (Figure [6](#F6){ref-type="fig"}c). H&E staining images of the major organs, including heart, liver, spleen, lung, and kidney, show negligible damage or inflammation, demonstrating minimal side effects of HSA-ICG-MB NP (Figure [7](#F7){ref-type="fig"}a). The routine blood analysis illustrates that there were no significant changes in blood panel parameters in the control group and NP-treated group (Figure [7](#F7){ref-type="fig"}b-m), suggesting low toxicity of NPs under the experimental conditions.

Conclusions
===========

In conclusion, HSA-ICG-MB NPs have been successfully developed for *in vivo* fluorescence and PA dual-modal imaging, and in situ visualization of therapeutic process based on the FRET mechanism. The unique features of the theranostic NPs include (1) molecular self-assembly and chemical crosslinking method for the controllable preparation of NPs with FDA-approved materials, (2) FRET-based *in vivo* NIR fluorescence imaging with a high S/B ratio and PA imaging with excellent resolution, and (3) FRET-based in situ visualization of treatment process for precision guidance of cancer PTT. In brief, this study presents a prospective NP system with FRET capability for cancer theranostics. The highly integrated NPs would be expected to facilitate the development of theranostic nanomedicine, holding a great promise for precision therapy and further applications.

Supplementary Material {#SM0}
======================

###### 
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:   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

TEM

:   Transmission electron microscopy

PBS

:   phosphate buffered saline

H&E

:   hematoxylin and eosin.

![The design and characterization of HSA-ICG-MB NPs. (a) Schematic illustration of the design and preparation of NPs by molecular assembly and chemical crosslinking method. (b) Molecular modeling showing the most favored binding sites of ICG and MB within the HSA matrix. (c) The normalized absorption and fluorescence emission spectra of MB and ICG. Spectra overlay is marked as orange. (d) The fluorescence spectra and (e) PA signals of HSA-ICG-MB complex with different ICG/MB ratios. C~MB~ = 5 µg/mL. Excitation wavelength is 600 nm. (f) TEM image of HSA-ICG-MB NPs, which are negatively stained with 2% phosphotungstic acid. (g) Size distribution of HSA-ICG-MB NPs. (h) Colloidal stability of HSA-ICG-MB NPs in PBS.](thnov08p0410g001){#F1}

![FRET-based fluorescence and PA techniques for monitoring the photothermal effect of HSA-ICG-MB NPs. (a) Scheme showing the changes of FRET-based fluorescence and PA signals during photothermal heating. (b) Time-dependent temperature elevation of HSA-ICG-MB NPs and PBS upon laser irradiation (808 nm, 1.0 W/cm^2^, C~ICG~ = 0.2 mg/mL). Excitation wavelength is 600 nm. (c) The fluorescence spectra of the HSA-ICG-MB NPs at different photothermal temperatures. (d) A plot of fluorescence intensity ratio (I~810~/I~685~) versus temperature to calibrate the thermometric scale for HSA-ICG-MB NPs. (e) The PA signals of MB (600 nm) and ICG (780 nm) channels at different photothermal temperatures. (f) A plot of PA signal ratio (I~780~/I~600~) versus photothermal temperature.](thnov08p0410g002){#F2}

![Cellular uptake and therapeutic visualization. (a) Confocal fluorescence images of C6 and bEnd.3 subcellular localization of free ICG and HSA-ICG-MB NPs after 3 h incubation, C~ICG~ = 2.5 μg/mL. Blue represents fluorescence of DAPI, and red represents fluorescence of ICG. (b) Confocal fluorescence images of C6 glioma cells upon NIR laser irradiation (808 nm, 1.0 W/cm^2^, C~ICG~ = 2.5 μg/mL). Green, red and blue represent fluorescence of MB, ICG and DAPI, respectively. (c) PA images of phantoms containing C6 glioma cells with photothermal treatments with different times (cell number = 100,000). Green and red represent PA signal of MB and ICG channels, respectively. (d) Fluorescence images of C6 glioma cells after photothermal treatment. Viable cells are stained green with calcein-AM, and the dead/later apoptotic cells are stained red with PI, C~ICG~ = 2.5 μg/mL. (e) Quantitative detection of C6 glioma cell viability following PTT. The data are shown as mean ± SD (n = 3).](thnov08p0410g003){#F3}

![*In vivo* fluorescence and PA dual-modal imaging of nude mice bearing C6 glioma tumors after intravenous injection of HSA-ICG-MB NPs. (a) *In vivo* fluorescence imaging at different signal channels and time intervals. MB channel with the excitation of 640 nm and emission of 700 nm, ICG channel with the excitation of 710 nm and emission of 800 nm, and FRET channel with the excitation of 640 nm and emission of 800 nm, C~ICG~ = 0.5 mg/kg. The black circles point out the tumor sites. (b) PA imaging of the nude mice bearing C6 glioma tumors injected with HSA-ICG-MB NPs at pre, 3, 6, and 24 h post injection, respectively, C~ICG~ = 0.5 mg/kg. (c) The fluorescence S/B ratios of different channels. (d) Biodistribution of HSA-ICG-MB NPs in mice determined by mean fluorescence intensity. (e) The mean PA intensity of tumor tissue at pre, 3, 6, and 24 h post injection, respectively. The data are shown as mean ±SD (n = 3).](thnov08p0410g004){#F4}

![*In vivo* FRET-based NIR fluorescence and PA dual-modal imaging for in situ visualization of cancer PTT. (a) Fluorescence and (b) PA imaging of nude mice bearing C6 glioma tumors during PTT at 24 h post injection of HSA-ICG-MB NPs, C~ICG~ = 2 mg/kg. The black circles point out the tumor sites. (c) Time-dependent heat generation of tumor tissue upon NIR laser irradiation (808 nm, 0.8 W/cm^2^). (d) A plot of S/B ratio in the tumor region versus laser irradiation time. (e) The dual-channel mean PA intensity of tumor tissue at 0 and 5 min NIR laser irradiation. The data are shown as mean ±SD (n=3).](thnov08p0410g005){#F5}

![*In vivo* cancer PTT in xenograft nude mice models with C6 glioma. (a) Tumor growth curves and (b) survival rates of nude mice bearing C6 glioma tumors after different treatments. (c) Body weights of tumor-bearing nude mice with different treatments during the 17 day evaluation period. (d) Representative photos of mice with different treatments. (e) H&E stained images and (f) TUNEL assay of tumor sections collected from different treatment groups 4 h post treatment. Apoptotic cells are labeled with green fluorescence. Blue represents fluorescence of DAPI.](thnov08p0410g006){#F6}

![*In vivo* toxicology studies. (a) H&E staining images of major organs collected from control group and NP-treated group at 30 days post injection of physiological saline and NPs (4 mg/kg). (b-m) Blood analysis of mice 30 days after injection of PBS and NPs with two different doses: (b) hematocrit (HCT), (c) hemoglobin concentration (HGB), (d) lymphocytes (Lymph), (e) mean corpuscular volume (MCV), (f) platelets (PLT), (g) monocyte (Mon), (h) number of white blood cells (WBC), (i) mean corpuscular hemoglobin concentration (MCHC), (g) mean platelet volume (MPV), (k) number of red blood cells (RBC), (l) number of neutrophilic granulocytes (Gran), and (m) platelet distribution width (PDW).](thnov08p0410g007){#F7}
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